
Immunoglobulin M is the first isotype to be expressed by the adaptive immune system in response to a foreign pathogen, during B cell development. It is typically present as the antigen receptor on the naïve B-cell surface, allow for the B cell to associate with the polypeptides CD79a and CD79b, which play roles in IgM cell signaling.
IgM is monomeric when first produced by plasma cells but when secreted can link to other IgM units to form a pentameric configuration containing a polypeptide J-chain. This occurs during maturation and antigenic stimulation and increases IgM’s avidity since there would be ten antigen-binding sites per pentameric molecule. Through interactions with the antigen, IgM can then opsonize it for destruction.
The detection of IgM can be used to diagnose patients from acute exposure to a pathogen, since IgM is typically linked with a primary immune response. However, it does not indicate whether the patient still has that pathogen or if it had been eliminated, since memory plasma cells help form immunological memory to generate antibodies against a pathogen for many more months and years to come.1
In addition, several disorders can be connected with IgM, such as X-linked Hyper-IgM Syndrome. This is a rare primary immune deficiency disorder, characterized by elevated IgM levels but deficient levels of other immunoglobulin isotypes, as well as defects in cellular immunity. Other disorders linked to IgM include Selective IgM Deficiency, Cold Agglutinin Disease, and Monoclonal Gammopathies.2
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Schroeder, H. W., & Cavacini, L. (2010). Structure and Function of Immunoglobulins. The Journal of Allergy and Clinical Immunology, 125(2 0 2), S41. https://doi.org/10.1016/J.JACI.2009.09.046
Sathe, A., & Cusick, J. K. (2022). Biochemistry, Immunoglobulin M. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK555995/
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and a……
Clinical drug development remains associated with a high failure rate, primarily……
Read on for the key trends of the NextGen Biomed 2026 conference held in London ……
Biointron’s Networking Lunch (At the Table: Antibody Discovery) was held at Cata……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



